Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) CFO Gabriel Morris acquired 1,418 shares of Immix Biopharma stock in a transaction on Wednesday, November 18th. The stock was acquired at an average cost of $7.06 per share, for a total transaction of $10,011.08. Following the purchase, the chief financial officer owned 292,847 shares of the company’s stock, valued at approximately $2,067,499.82. This represents a 0.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Immix Biopharma Stock Down 1.0%
Shares of NASDAQ IMMX opened at $7.04 on Friday. Immix Biopharma, Inc. has a 12-month low of $3.78 and a 12-month high of $15.10. The firm’s 50-day simple moving average is $9.35 and its 200 day simple moving average is $9.61. The company has a market cap of $590.02 million, a price-to-earnings ratio of -8.48 and a beta of 0.29.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). On average, equities analysts expect that Immix Biopharma, Inc. will post -0.75 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of IMMX. Russell Investments Group Ltd. increased its holdings in Immix Biopharma by 44.4% during the third quarter. Russell Investments Group Ltd. now owns 4,743 shares of the company’s stock worth $49,000 after buying an additional 1,459 shares during the last quarter. Profund Advisors LLC lifted its position in shares of Immix Biopharma by 7.3% in the third quarter. Profund Advisors LLC now owns 31,431 shares of the company’s stock valued at $327,000 after buying an additional 2,126 shares during the last quarter. Mathes Company Inc. boosted its stake in shares of Immix Biopharma by 23.5% during the 3rd quarter. Mathes Company Inc. now owns 13,150 shares of the company’s stock worth $137,000 after acquiring an additional 2,500 shares during the period. Legal & General Group Plc acquired a new position in shares of Immix Biopharma during the 2nd quarter worth approximately $41,000. Finally, Nisa Investment Advisors LLC acquired a new position in shares of Immix Biopharma during the 3rd quarter worth approximately $52,000. 11.26% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research firms have commented on IMMX. HC Wainwright lifted their target price on shares of Immix Biopharma from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Monday. Morgan Stanley increased their price target on shares of Immix Biopharma from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday. Needham & Company LLC lifted their price target on shares of Immix Biopharma from $21.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Mizuho dropped their price objective on Immix Biopharma from $23.00 to $22.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a research note on Wednesday, September 30th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Immix Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $24.14.
View Our Latest Research Report on Immix Biopharma
About Immix Biopharma
Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.
Featured Stories
- Five stocks we like better than Immix Biopharma
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
